IDGX.F Stock Overview
Integrated Diagnostics Holdings plc, a consumer healthcare company, provides various medical diagnostics services to patients.
Integrated Diagnostics Holdings Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.68|
|52 Week High||US$1.50|
|52 Week Low||US$0.65|
|1 Month Change||-10.46%|
|3 Month Change||-37.91%|
|1 Year Change||-25.22%|
|3 Year Change||-44.45%|
|5 Year Change||n/a|
|Change since IPO||-44.08%|
Recent News & Updates
|IDGX.F||US Healthcare||US Market|
Return vs Industry: IDGX.F underperformed the US Healthcare industry which returned 12.5% over the past year.
Return vs Market: IDGX.F underperformed the US Market which returned -12.7% over the past year.
|IDGX.F Average Weekly Movement||n/a|
|Healthcare Industry Average Movement||9.6%|
|Market Average Movement||8.1%|
|10% most volatile stocks in US Market||17.3%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: Insufficient data to determine IDGX.F's volatility over the past 3 months.
Volatility Over Time: Insufficient data to determine IDGX.F's volatility change over the past year.
About the Company
|1979||6,388||Hend El Sherbini||https://www.idhcorp.com|
Integrated Diagnostics Holdings plc, a consumer healthcare company, provides various medical diagnostics services to patients. It offers approximately 2,000 diagnostic test services, including immunology, microbiology, hematology, endocrinology, clinical chemistry, molecular biology, cytogenetics, histopathology, and radiology. The company operates in Egypt, Jordan, Sudan, and Nigeria.
Integrated Diagnostics Holdings Fundamentals Summary
|IDGX.F fundamental statistics|
Is IDGX.F overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|IDGX.F income statement (TTM)|
|Cost of Revenue||ج.م2.58b|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||2.31|
|Net Profit Margin||26.22%|
How did IDGX.F perform over the long term?See historical performance and comparison
12.7%Current Dividend Yield
Is IDGX.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 4/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for IDGX.F?
Other financial metrics that can be useful for relative valuation.
|What is IDGX.F's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does IDGX.F's PE Ratio compare to its peers?
|IDGX.F PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
INNV InnovAge Holding
CCRN Cross Country Healthcare
CO Global Cord Blood
IDGX.F Integrated Diagnostics Holdings
Price-To-Earnings vs Peers: IDGX.F is good value based on its Price-To-Earnings Ratio (7.5x) compared to the peer average (19.5x).
Price to Earnings Ratio vs Industry
How does IDGX.F's PE Ratio compare vs other companies in the US Healthcare Industry?
Price-To-Earnings vs Industry: IDGX.F is good value based on its Price-To-Earnings Ratio (7.5x) compared to the US Healthcare industry average (19.5x)
Price to Earnings Ratio vs Fair Ratio
What is IDGX.F's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||7.5x|
|Fair PE Ratio||n/a|
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate IDGX.F's Price-To-Earnings Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of IDGX.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: IDGX.F ($0.68) is trading below our estimate of fair value ($2.49)
Significantly Below Fair Value: IDGX.F is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
How is Integrated Diagnostics Holdings forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Future Growth Score4/6
Future Growth Score 4/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IDGX.F's forecast earnings growth (15.4% per year) is above the savings rate (1.9%).
Earnings vs Market: IDGX.F's earnings (15.4% per year) are forecast to grow faster than the US market (12.8% per year).
High Growth Earnings: IDGX.F's earnings are forecast to grow, but not significantly.
Revenue vs Market: IDGX.F's revenue (10.9% per year) is forecast to grow faster than the US market (7.9% per year).
High Growth Revenue: IDGX.F's revenue (10.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: IDGX.F's Return on Equity is forecast to be very high in 3 years time (60%).
Discover growth companies
How has Integrated Diagnostics Holdings performed over the past 5 years?
Past Performance Score6/6
Past Performance Score 6/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IDGX.F has high quality earnings.
Growing Profit Margin: IDGX.F's current net profit margins (26.2%) are higher than last year (24.8%).
Past Earnings Growth Analysis
Earnings Trend: IDGX.F's earnings have grown significantly by 30.8% per year over the past 5 years.
Accelerating Growth: IDGX.F's earnings growth over the past year (69.5%) exceeds its 5-year average (30.8% per year).
Earnings vs Industry: IDGX.F earnings growth over the past year (69.5%) exceeded the Healthcare industry 9.5%.
Return on Equity
High ROE: IDGX.F's Return on Equity (48.6%) is considered outstanding.
Discover strong past performing companies
How is Integrated Diagnostics Holdings's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: IDGX.F's short term assets (EGP3.4B) exceed its short term liabilities (EGP2.5B).
Long Term Liabilities: IDGX.F's short term assets (EGP3.4B) exceed its long term liabilities (EGP1.2B).
Debt to Equity History and Analysis
Debt Level: IDGX.F has more cash than its total debt.
Reducing Debt: IDGX.F's debt to equity ratio has increased from 2.5% to 3.3% over the past 5 years.
Debt Coverage: IDGX.F's debt is well covered by operating cash flow (2132.5%).
Interest Coverage: IDGX.F earns more interest than it pays, so coverage of interest payments is not a concern.
Discover healthy companies
What is Integrated Diagnostics Holdings's current dividend yield, its reliability and sustainability?
Dividend Score 3/6
Cash Flow Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: IDGX.F's dividend (12.74%) is higher than the bottom 25% of dividend payers in the US market (1.53%).
High Dividend: IDGX.F's dividend (12.74%) is in the top 25% of dividend payers in the US market (4.1%)
Stability and Growth of Payments
Stable Dividend: IDGX.F has been paying a dividend for less than 10 years and during this time payments have been volatile.
Growing Dividend: IDGX.F's dividend payments have increased, but the company has only paid a dividend for 6 years.
Earnings Payout to Shareholders
Earnings Coverage: With its high payout ratio (94.1%), IDGX.F's dividend payments are not well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonable cash payout ratio (72.2%), IDGX.F's dividend payments are covered by cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Hend El Sherbini (53 yo)
Prof. Dr. Hend El Sherbini has been Group Chief Executive Officer of Integrated Diagnostics Holdings plc since 2012 and as its Executive Director since December 23, 2014. Prof. Dr. El Sherbini serves as th...
CEO Compensation Analysis
Compensation vs Market: Hend's total compensation ($USD467.51K) is below average for companies of similar size in the US market ($USD2.70M).
Compensation vs Earnings: Hend's compensation has been consistent with company performance over the past year.
Experienced Board: IDGX.F's board of directors are considered experienced (7.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Integrated Diagnostics Holdings plc's employee growth, exchange listings and data sources
- Name: Integrated Diagnostics Holdings plc
- Ticker: IDGX.F
- Exchange: OTCPK
- Founded: 1979
- Industry: Health Care Services
- Sector: Healthcare
- Implied Market Cap: US$540.000m
- Shares outstanding: 600.00m
- Website: https://www.idhcorp.com
Number of Employees
- Integrated Diagnostics Holdings plc
- 12 Castle Street
- Saint Helier
- JE2 3RT
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/08/05 00:00|
|End of Day Share Price||2022/07/29 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.